Stream 3 Session #11: Drug Discovery in Metabolism
Tracks
Meeting Room 105 & 106
| Friday, August 21, 2026 |
| 4:00 PM - 6:00 PM |
| Meeting Room 105 & 106 (Level 1) |
Speaker
Prof Zane Andrews
Researcher
Monash University
Chairperson
Biography
Dr Jacky Stoeckli
Senior Research Fellow
The Charles Perkins Centre
Chairperson
Biography
James Trevaskis
Associate Vice President
Eli Lilly
Next generation amylin analogs for the treatment of metabolic disease
4:00 PM - 4:25 PMBiography
Assoc Prof Samantha Hocking
Endocrinologist
Royal Prince Alfred Hospital
From semaglutide to triple agonists: are we solving obesity or uncovering new questions?
4:25 PM - 4:50 PMBiography
Prof Garron Dodd
Professor
The University Of Melbourne
Targeting the Brain to Treat Type-2 Diabetes
4:50 PM - 5:15 PMBiography
Prof Mark Sleeman
Vice President, Research
Regeneron Pharmaceuticals
Invited Talk
5:15 PM - 5:40 PMBiography
Dr Sahar Keshvari
Senior Research Officer
Mater Research / University of Queensland
Macrophage Colony Stimulating Factor (CSF1) promotes resolution of fibrosis and steatosis in preclinical models of metabolic dysfunction-associated steatotic liver disease.
5:40 PM - 5:55 PMBiography
Dr Sahar Keshvari is an emerging leader and NHMRC Investigator Grant recipient driving innovative research on immune‑metabolic pathways. Her work is uncovering new mechanisms and potential treatments for diabetes‑related metabolic dysfunction and liver disease, aiming to transform outcomes for people living with these conditions.
